Xenon Pharmaceuticals Quick Ratio 2012-2022 | XENE
Historical quick ratio values for Xenon Pharmaceuticals (XENE) over the last 10 years.
| Xenon Pharmaceuticals Quick Ratio Historical Data |
| Date |
Current Assets - Inventory |
Current Liabilities |
Quick Ratio |
| 2022-03-31 |
$0.00B |
$0.01B |
0.00 |
| 2021-12-31 |
$0.00B |
$0.01B |
0.00 |
| 2021-09-30 |
$0.00B |
$0.01B |
0.00 |
| 2021-06-30 |
$0.00B |
$0.02B |
0.00 |
| 2021-03-31 |
$0.00B |
$0.01B |
0.00 |
| 2020-12-31 |
$0.00B |
$0.02B |
0.00 |
| 2020-09-30 |
$0.00B |
$0.02B |
0.00 |
| 2020-06-30 |
$0.00B |
$0.02B |
0.00 |
| 2020-03-31 |
$0.00B |
$0.05B |
0.00 |
| 2019-12-31 |
$0.00B |
$0.04B |
0.00 |
| 2019-09-30 |
$0.00B |
$0.01B |
0.00 |
| 2019-06-30 |
$0.00B |
$0.01B |
0.00 |
| 2019-03-31 |
$0.00B |
$0.01B |
0.00 |
| 2018-12-31 |
$0.00B |
$0.00B |
0.00 |
| 2018-09-30 |
$0.00B |
$0.00B |
0.00 |
| 2018-06-30 |
$0.00B |
$0.00B |
0.00 |
| 2018-03-31 |
$0.00B |
$0.00B |
0.00 |
| 2017-12-31 |
$0.00B |
$0.00B |
0.00 |
| 2017-09-30 |
$0.00B |
$0.00B |
0.00 |
| 2017-06-30 |
$0.00B |
$0.00B |
0.00 |
| 2017-03-31 |
$0.00B |
$0.00B |
0.00 |
| 2016-12-31 |
$0.00B |
$0.00B |
0.00 |
| 2016-09-30 |
$0.00B |
$0.00B |
0.00 |
| 2016-06-30 |
$0.00B |
$0.00B |
0.00 |
| 2016-03-31 |
$0.00B |
$0.00B |
0.00 |
| 2015-12-31 |
$0.00B |
$0.00B |
0.00 |
| 2015-09-30 |
$0.00B |
$0.01B |
0.00 |
| 2015-06-30 |
$0.00B |
$0.01B |
0.00 |
| 2015-03-31 |
$0.00B |
$0.02B |
0.00 |
| 2014-12-31 |
$0.00B |
$0.01B |
0.00 |
| 2014-09-30 |
$0.00B |
$0.02B |
0.00 |
| 2014-06-30 |
$0.00B |
|
0.00 |
| 2014-03-31 |
$0.00B |
|
0.00 |
| 2013-12-31 |
$0.00B |
|
0.00 |
| 2013-09-30 |
$0.00B |
|
0.00 |
| 2012-12-31 |
$0.00B |
$0.02B |
0.00 |
| 2011-12-31 |
$0.00B |
|
0.00 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$1.407B |
$0.018B |
|
Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is focused on the development of medicines through the application of its proprietary discovery platform, which it refer to as Extreme Genetics. Xenon is developing proprietary product candidates for the treatment of both orphan as well as more prevalent diseases. The company offers Glybera (R), a gene therapy for the treatment of lipoprotein lipase deficiency, an orphan disorder. Xenon Pharmaceuticals Inc. is headquartered in Burnaby, Canada.
|
